Raymond James Financial Services Advisors, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$37.42 - $51.61 $52,649 - $72,615	-1,407 Reduced 8.99%	14,236 $585,000
Q1 2024 Apr 22, 2024	SELL	$43.02 - $53.69 $169,283 - $211,270	-3,935 Reduced 20.1%	15,643 $730,000
Q4 2023 Jan 16, 2024	SELL	$31.73 - $49.19 $80,276 - $124,450	-2,530 Reduced 11.44%	19,578 $936,000
Q3 2023 Oct 24, 2023	BUY	$34.92 - $46.66 $433,112 - $578,723	12,403 Added 127.8%	22,108 $788,000
Q2 2023 Jul 25, 2023	BUY	$37.35 - $52.15 $362,481 - $506,115	9,705 New	9,705 $447,000
Q2 2019 Aug 06, 2019	SELL	$54.93 - $74.36 $160,889 - $217,800	-2,929 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$39.87 - $69.36 $116,779 - $203,155	2,929 New	2,929 $203,000

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$428 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$241 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$220 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$179 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$132 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account